Form 4: Corcept Therapeutics Executive William Guyer Executes Stock Option and Sells Shares

William Guyer, Chief Development Officer of Corcept Therapeutics, exercised stock options and sold 10,000 shares of common stock at $32 per share on June 3, 2024, according to a recent SEC filing.

Summary

• On June 3, 2024, William Guyer, the Chief Development Officer of Corcept Therapeutics, exercised stock options to acquire 10,000 shares of common stock at a price of $19.26 per share.
• Simultaneously, Guyer sold 10,000 shares of Corcept Therapeutics common stock at $32 per share.
• Following these transactions, Guyer directly owns 6,039 shares of Corcept Therapeutics common stock.
• This includes 478 shares underlying unvested restricted stock awards granted on September 1, 2023, and 609 shares underlying unvested restricted stock units granted on December 1, 2023.
• Guyer also holds options to purchase 50,000 shares of common stock.

Sentiment

Score: 5

Explanation: Neutral sentiment as it's a standard disclosure of insider trading activity. The transaction itself doesn't inherently indicate positive or negative sentiment about the company's future.

Industry Context

This filing is a routine disclosure of insider transactions. Monitoring such filings can provide insights into management's perspective on the company's stock and future prospects, although one transaction is not necessarily indicative of a trend.

Stakeholder Impact

• The transaction could have a minor impact on shareholders, depending on how the market interprets the insider's actions.

Key Dates